ILNS.. Intellect Neurosciences, Inc

[Aufan 1983]

One to watch that I know very little about. Stockcharts.com doesn't have a chart so I had to dig one up from Bigcharts. If the move continues I may jump in just to see where this goes.

This made a HUGE move yesterday on no news that I could find. Are people playing the bounce, a group play or has news leaked out?

I don't have a position in this but it will be interesting today to see if it continues or crashes and burns.

They have some very interesting irons in the fire as you can see from the news below.

SOME PREVIOUS NEWS HEADLINES:

http://biz.yahoo.com/prnews/070919/nyw017.html?.v=101

Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimer's Vaccine in 19 Countries
Wednesday September 19, 7:45 am ET



http://biz.yahoo.com/prnews/070920/nyth015.html?.v=101

Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
Thursday September 20, 7:45 am ET


[IMG][/IMG]

[Aufan 1983]

Bloomberg.com shows the float @ 35.07 million which is the same as the o/s that is shown

[Aufan 1983]

Up 20% but not much volume.

[Aufan 1983]

GapperZZZZZ..... Closed @ .56 Friday

Today: .69 x .70

[Aufan 1983]

YOOO HOOOO 79 x 80 :D :D :D

[BadThad]

Nice find bro, this stock was over $3/share.....it might see that level again. I can't find much either, the chart on TDA only goes back to about May 2007....IPO then?

[Aufan 1983]

Originally Posted by BadThad

Nice find bro, this stock was over $3/share.....it might see that level again. I can't find much either, the chart on TDA only goes back to about May 2007....IPO then?

Same here. I think it must have been the IPO but I'm not sure. Ran way too high this morning and has stalled out. Hopefully the volume will pick up

[Rock Sexton]

Pincher play with news ......

Intellect Neurosciences, Inc. Receives Notice of Allowance for Patent on Alzheimer's Drug From the Canadian Patent and Trademark Office

NEW YORK, Aug. 9, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc (OTCBB:ILNS - News) announced that it has received a Notice of Allowance from the Canadian Patent and Trademark Office for a new patent related to OX1 (OXIGON(TM)), the Company's clinical-stage drug candidate that has disease-modifying potential for Alzheimer's and other neurodegenerative disorders. OX1 is an orally-administered, brain-penetrating, naturally-occurring, copper-binding small molecule targeting multiple mechanisms that contribute significantly to the underlying pathology of Alzheimer's disease. The Company has successfully tested OX1 in human Phase I safety trials, providing initial positive data on safety and tolerability of the drug.

The Notice of Allowance is a written communication from the patent office stating that the application has been allowed and will be granted as a Canadian patent. Patents for OX1 have been issued in the United States, Europe and other countries and are pending in Japan and Mexico. The patents are jointly owned by New York University and the University of South Alabama and are licensed exclusively to Intellect Neurosciences.

Dr. Daniel Chain, Intellect's Chairman and CEO, commented: "OX1 is the most advanced candidate in our internal pipeline and has the potential to slow down or arrest Alzheimer's disease in the early stages by stabilizing amyloid beta in non-toxic form and preventing oxidative damage leading to inflammation and cell death. Moreover, based on OX1's mechanism of action, we believe it has applications for other disease indications as well. The Notice of Allowance of a new patent in Canada relating to OX1 strengthens our intellectual property portfolio and the competitive advantage of our internal drug development pipeline, which boasts clinical stage and preclinical programs. Our goal is to develop OX1 through strategic relationships with major pharmaceutical companies from whom we could obtain R&D funding and revenues from license fees, milestone payments, and royalties. We intend to build off of our previous successes in granting royalty-bearing licenses to major pharmaceutical companies that are developing drugs in Phase 2 and Phase 3 clinical trials for Alzheimer's disease."

Intellect Neurosciences, Inc. Receives Notice of Allowance for Patent on Alzheimer's Drug From the Canadian Patent and Trademark Office - Yahoo! Finance